Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

ß-Thalassemia Major With Autologous CD34+ Hematopoietic Progenitor Cells Transduced With TNS9.3.55 a Lentiviral Vector Encoding the Normal Human ß-Globin Gene

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2014 by Memorial Sloan-Kettering Cancer Center
Sponsor:
Information provided by (Responsible Party):
Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT01639690
First received: July 11, 2012
Last updated: September 4, 2014
Last verified: September 2014

July 11, 2012
September 4, 2014
July 2012
July 2015   (final data collection date for primary outcome measure)
  • safety [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]

    of transplanted autologous CD34+ hematopoietic cells that are transduced ex vivo with TNS9.3.55 and transplanted in subjects with ß-thalassemia major conditioned with a reduced-intensity non-myeloablative preparative regimen.

    1. The occurrence of insertional oncogenesis, which will be investigated by monitoring peripheral blood cell counts and leukocyte clonality using FACS analysis, qPCR for vector. copy number, LAM-PCR and/or 454 sequencing;
    2. The generation of a replication-competent lentivirus (RCL).
    3. The safety of a low dose non-myeloablative conditioning regimen
  • tolerability [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    of transplanted autologous CD34+ hematopoietic cells that are transduced ex vivo with TNS9.3.55 & transplanted in subjects with ß-thalassemia major conditioned with a reduced-intensity non-myeloablative preparative regimen. monitoring the following: 1. The occurrence of insertional oncogenesis, which will be investigated by monitoring peripheral blood cell counts & leukocyte clonality using FACS analysis, qPCR for vector. copy number, LAM-PCR and/or 454 sequencing; 2.The generation of a replication-competent lentivirus (RCL). 3.The safety of a low dose non-myeloablative conditioning regimen
  • safety [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]

    of Thalagen™-CD34+, in this patient cohort. This will be evaluated through monitoring the following:

    1. The occurrence of insertional oncogenesis, which will be investigated by monitoring peripheral blood cell counts and leukocyte clonality using FACS analysis, qPCR for vector. copy number, LAM-PCR and/or 454 sequencing;
    2. The generation of a replication-competent lentivirus (RCL).
    3. The safety of a low dose non-myeloablative conditioning regimen.
  • tolerability [ Time Frame: 2 years ] [ Designated as safety issue: No ]

    of Thalagen™-CD34+, in this patient cohort. This will be evaluated through monitoring the following:

    1. The occurrence of insertional oncogenesis, which will be investigated by monitoring peripheral blood cell counts and leukocyte clonality using FACS analysis, qPCR for vector. copy number, LAM-PCR and/or 454 sequencing;
    2. The generation of a replication-competent lentivirus (RCL).
    3. The safety of a low dose non-myeloablative conditioning regimen.
Complete list of historical versions of study NCT01639690 on ClinicalTrials.gov Archive Site
  • the level of engraftment [ Time Frame: 2 years ] [ Designated as safety issue: No ]

    of the genetically modified autologous CD34+ cells and expression of the transduced ß-globin gene as measured by: Blood for measurement of vector copy number and transgene expression in blood cells at months 1, 2 and 3.

    - Bone Marrow Samples for evaluation of CFU, BFU-E gene+ colonies and Q-PCR will be tested at month 1.

  • The frequency of post transplant palliative transfusions [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    The number of red blood cell transfusions after engraftment will be quantitatively evaluated for efficacy purposes.
the level of engraftment [ Time Frame: 2 years ] [ Designated as safety issue: No ]

of transduced CD34+ cells and the biological activity of the globin vector, as measured by:

1. The presence and expression of the transduced ß-globin transgene in peripheral blood cells; and the presence and expression of the transgene in hematopoietic progenitor cells in bone marrow; 2. The frequency of palliative transfusions subsequent to transplantation.

Not Provided
Not Provided
 
ß-Thalassemia Major With Autologous CD34+ Hematopoietic Progenitor Cells Transduced With TNS9.3.55 a Lentiviral Vector Encoding the Normal Human ß-Globin Gene
A Phase I Clinical Trial for the Treatment of ß-Thalassemia Major With Autologous CD34+ Hematopoietic Progenitor Cells Transduced With TNS9.3.55 a Lentiviral Vector Encoding the Normal Human ß-Globin Gene

The patient has inherited ß-thalassemia major through the genes. These genes have mistakes in them, so the body cannot make normal red blood cells. Stem cells are made in the bone marrow. They are the earliest form of blood cells.

This study is being done to see if the investigators can make the stem cells produce normal red blood cells and hemoglobin. The investigators do this by collecting the stem cells. The genes with mistakes are removed from the cells. These cells are then treated so they have the corrected gene for making normal hemoglobin. These treated cells are given back to the patient through an injection (shot) in the vein. This is also known as gene transfer. In order for the body to accept these cells, the patient will need to receive a low dose of a drug called busulfan. It is a drug that will prepare the body to receive the new stem cells.

This study will let the investigators know:

  • If it is safe to give the patient the treated stem cells
  • If the treated stem cells will go into the bone marrow without causing side effects.

Gene transfer has been used for the past five years. It has been successful in treating many blood disorders. At least 20 patients have received the type of treatment that the patient will get on this study. This treatment for B-thalassemia major was developed here at Memorial Sloan Kettering (MSK). It was studied for a long time in the lab before being given to patients.

Not Provided
Interventional
Phase 1
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Confirmed Diagnosis of ß-thalassemia Major
Genetic: Autologous CD34+ cells transduced with TNS9.3.55
Patients will receive Filgrastim followed by apheresis of peripheral blood stem cells. CD34+ cells will be purified and transduced ex vivo. Transduced cells will be frozen in several aliquots whenever possible while vector copy number determination and biosafety testing are performed. Patients will be treated in the outpatient and/or inpatient units, and receive intravenous busulfan (8mg/kg) as non-myeloablative conditioning. Patients will be administered 2-12 x 10^6 transduced CD34+ cells per kg in 1 or several infusions. A back-up of 2 x 10^6 untransduced CD34+ cells per kg will be preserved for every patient.
Other Names:
  • Patient treatment with Filgrastim will last for up to 6 days with apheresis
  • collection on days 4 and 5 or days 5 or 6 if required. Reduced Intensity Conditioning will
  • consist of two days of busulfan treatment with an interval of two days prior to transplantation.
  • Intravenous infusion of autologous CD34+ cells transduced with TNS9.3.55 will
  • be administered over 15-30 minutes in a volume of approximately 50 to 250 mL
  • on day 0. Subsequent infusions of autologous CD34+ cells transduced with TNS9.3.55
  • may be administered on day +1 or thereafter.
Experimental: Autologous CD34+ cells transduced with TNS9.3.55
An open label study using a non-myeloablative conditioning regimen of busulfan and 1 or several infusions of autologous hematopoietic stem cells transduced with a lentiviral vector encoding the human ß-globin gene.
Intervention: Genetic: Autologous CD34+ cells transduced with TNS9.3.55
Boulad F, Wang X, Qu J, Taylor C, Ferro L, Karponi G, Bartido S, Giardina P, Heller G, Prockop SE, Maggio A, Sadelain M, Rivière I. Safe mobilization of CD34+ cells in adults with β-thalassemia and validation of effective globin gene transfer for clinical investigation. Blood. 2014 Mar 6;123(10):1483-6. doi: 10.1182/blood-2013-06-507178. Epub 2014 Jan 15.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
10
July 2015
July 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subjects must be 18 years or older
  • Subjects may be of either gender or of any ethnic background
  • Subjects must have a confirmed diagnosis of ß-thalassemia major and have been enrolled in a hypertransfusion program with a confirmed annual transfusion of ≥100 mL/kg/yr but < 200 mL/kg/yr, AND ≥ 8 transfusions of blood per year over a minimum of two years.
  • Patients must NOT have an HLA-matched sibling
  • Patients must be off hydroxyurea (HU) or erythropoietin (EPO) treatment for at least three months prior to entry onto the study
  • Subjects must have a performance score of Karnofsky ≥70% at the time of entry into the study.
  • Subjects must have liver iron value of < 15 mg/g/dry weight Iron quantitation may be performed by imaging such as T2*MRI or by biopsy
  • Subjects must have no evidence of cirrhosis** of the liver. Fibrosis of the liver can be tested by Fibroscan (47, 48, 49), or by liver biopsy. These should be performed within approximately a one year period prior to entry onto the study.
  • Subjects with an evaluation of cardiac function indicating:
  • normal function on MUGA scan (Multiple Gated Acquisition scan) or other methodology.

And

  • Patients must have a left ventricular ejection fraction (LVEF) of ≥ 60% and/or T2*MRI cardiac evaluation with T2* ≥20 milliseconds
  • Subjects with asymptomatic pulmonary function based on Lung Diffusion Testing DLCO Test DLCO ≥ 50% of predicted (corrected for hemoglobin)
  • Subjects with a determination of renal function based on: serum creatinine < than or = to 1.5 mg/dL or if serum creatinine is outside the normal range, then CrCl > 60-ml/min/1.73 m2
  • Subjects must have adequate hepatic function based on:
  • < 3 x ULN ALT and
  • < 2.0 total serum bilirubin (unless secondary to hemolysis)
  • Patients must be available for follow-up evaluations at 30, 60, 180 days post BMT and yearly thereafter indefinitely.

    • The possibility of unrelated donor stem cell transplantation will be discussed with patients, and a "preliminary" search for an unrelated donor may be done at the request of the patient. However, the finding of a potential HLA-matched unrelated donor will not exclude the patient from participating into this trial).

      • As the inclusion criteria are more specific than the Lucarelli/Pesaro thalassemia pre-transplant classification (Class 1,2 or 3 according to presence or absence of fibrosis, adequate chelation and/or hepatomegaly), the criteria stated above will be used in lieu of the Lucarelli/Pesaro classification.

Exclusion Criteria:

  • Active infections including Hepatitis B and Hepatitis C***,
  • Active infections including HTLV 1 and 2, and HIV 1 and 2
  • Patients with treated HLTV or HIV
  • Diabetes Mellitus
  • Bone Marrow myelodysplasia and/or chromosomal abnormalities
  • Female patient pregnant or breast feeding
  • Patients with uncontrolled seizure disorders
  • Patients with severe pulmonary hypertension Tricuspid Jet velocity > 2.5 m/sec
  • Family history of familial cancer syndromes (leukemia, breast, ovarian, colorectal, etc.)

    *** Definition of active Hepatitis C include:

  • Positive HCV RNA Viral load by quantitative PCR testing Or if Negative HCV RNA viral load BUT on antiviral treatment
  • Liver biopsy with pathologic evidence of
  • Necrosis and inflammation around the portal areas - piecemeal necrosis or interface hepatitis or necrosis of hepatocytes and focal inflammation in the liver parenchyma.
  • Inflammatory cells in the portal areas ("portal inflammation").
  • Fibrosis, with early stages being confined to the portal tracts, intermediate stages being expansion of the portal tracts and bridging between portal areas or to the central area, and late stages being frank cirrhosis characterized by architectural disruption of the liver with fibrosis and regeneration.
Both
18 Years and older
No
Contact: Farid Boulad, MD 212-639-6684
Contact: Susan Prockop, MD 212-639-6715
United States
 
NCT01639690
10-164
Not Provided
Memorial Sloan-Kettering Cancer Center
Memorial Sloan-Kettering Cancer Center
Not Provided
Principal Investigator: Farid Boulad, MD Memorial Sloan-Kettering Cancer Center
Memorial Sloan-Kettering Cancer Center
September 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP